Skip to main content
Signal8
Launch Terminal

NeuroPace Inc (NPCE)

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

Sector: Surgical & Medical Instruments & Apparatus

Industry: Medical - Devices

NeuroPace, Inc. logo

NeuroPace, Inc.

NASDAQ:NPCEHealthcare
-5.46%$12.30
AH$12.30+0.00%vs close
Mkt Cap$422.19M
Float24.06M
O/S34.32M
Vol
$ Vol
RVOL
Inst Own77.4%
SI3.7%
Earnings
Dilution
NeuroPace, Inc. logoNASDAQ:NPCE$12.30-5.46%
Phase Distribution
9 lead-sponsored trials·2 active·6 completed
Phase 23
Phase 31
Phase 41
Not applicable4
(3 more as collaborator)
Status Overview
Recruiting1
Active, not recruiting1
Completed6
Stopped1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 4
    Completed

    RNS® System LTT Study

    RNS® System

    Epilepsy

    Enrollment
    230
    Start
    Apr 2006
    Primary Completion
    May 2018
    Completion
    May 2018
    NCT00572195
  • Phase 3
    Completed

    RNS® System Pivotal Study

    RNS® System implantation, RNS® System responsive stimulation

    Epilepsy

    Enrollment
    240
    Start
    Dec 2005
    Primary Completion
    Oct 2009
    Completion
    May 2011
    NCT00264810
  • Phase 2
    Completed

    RNS® System Feasibility Study

    RNS® System implantation, RNS® System responsive stimulation

    Epilepsy

    Enrollment
    70
    Start
    Jan 2004
    Primary Completion
    May 2006
    Completion
    Dec 2007
    NCT00079781
  • Phase 2
    Completed

    Study of an External Responsive Neurostimulator System on Epileptiform Activity

    external Responsive Neurostimulator (eRNS) System

    Epilepsy

    Enrollment
    150
    Start
    Mar 2002
    Primary Completion
    Apr 2007
    Completion
    Mar 2008
    NCT00158067
  • Phase 2
    Active, not recruiting

    RNS System LGS Feasibility Study

    RNS System

    Epilepsy, Lennox Gastaut Syndrome +3

    Enrollment
    24
    Start
    Oct 2022
    Primary Completion
    Nov 2026est.
    Completion
    Dec 2026est.
    NCT05339126
  • Observational
    Completed

    RNS® System Epilepsy Post-Approval Study

    RNS System

    Epilepsy

    Enrollment
    345
    Start
    Jun 2015
    Primary Completion
    Dec 2023
    Completion
    Jan 2026
    NCT02403843
  • Not applicable
    Terminated

    RNS System RESPONSE Study

    RNS System

    Epilepsy, Partial Seizure +3

    Enrollment
    9
    Start
    Oct 2021
    Primary Completion
    May 2025
    Completion
    May 2025
    NCT04839601
  • Not applicable
    Completed

    RNS System NAUTILUS Study

    Responsive stimulation, Sham stimulation

    Epilepsy, Idiopathic Generalized Epilepsy +1

    Enrollment
    100
    Start
    Aug 2022
    Primary Completion
    Apr 2025
    Completion
    Mar 2026
    NCT05147571
  • Observational
    Enrolling by invitation

    RNS System for Drug-Resistant Focal Epilepsy in Adolescents: A Real-World Study

    NeuroPace RNS System

    Focal Epilepsy, Drug-resistant Focal Epilepsy

    Enrollment
    100
    Start
    Sep 2026est.
    Primary Completion
    Feb 2027est.
    Completion
    May 2027est.
    NCT07823465
Search ClinicalTrials.gov for “NeuroPace”